Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 398

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 398
---
 growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period. 219

We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non -affiliatesexceeds $700 million as of the prior June 30 th, and (2) the date on which we have issued more than $1.00 billion in non -convertibledebt securities during the prior three -yearperiod. References herein to “emerging growth company” shall have the meaning associated with it in the JOBS Act. Directors and Executive Officers NorthView’s directors and executive officers are as follows:

| Name           |     | Age |     | Title                                         |
| Jack Stover    |     |  71 |     | Co-Founder, Director, Chief Executive Officer |
| Fred Knechtel  |     |  64 |     | Co-Founder, Director, Chief Financial Officer |
| Peter O’Rourke |     |  52 |     | Chairman of the Board, Independent Director   |
| Ed Johnson     |     |  63 |     | Independent Director                          |
| Lauren Chung   |     |  48 |     | Independent Director                          |

Jack Stover — Co-Founder , Director and Chief Executive Officer Jack Stover has served as our Chief Executive Officer and director since inception. Since November 2018, Mr.Stover has been director, member of the compensation committee, chairman of the audit committee, chairman of the special deal committee and recently Lead Independent Director of Traws Pharma Inc. (TRAW) (formerly Onconova Therapeutics, Inc. (ONTX)) a Nasdaq -basednovel small molecule anti -viraland oncology therapeutics company with products in various clinical trials. Mr.Stover has also been a member of the board of directors of Stero Therapeutics